Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice-Reference-Cited by-同舟云学术

Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice

Published:2011-06 Issue:2 Volume:216 Page:313-320
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Bhaskar Vinay,Yin Johnny,Mirza Amer M.,Phan Dan,Vanegas Sandra,Issafras Hassan,Michelson Kristen,Hunter John J.,Kantak Seema S.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference21 articles.

1. Blocking IL-1 in systemic inflammation;Dinarello;J Exp Med,2005

2. IL-1 cytokines in cardiovascular disease: diagnostic, prognostic and therapeutic implications;Apostolakis;Cardiovasc Hematol Agents Med Chem,2008

3. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals;Duewell;Nature,2010

4. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding;Chamberlain;PLoS One,2009

5. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size;Devlin;Proc Natl Acad Sci U S A,2002

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Serum NLRP1 Level and Coronary Artery Calcification: From Association to Development of a Risk-Prediction Nomogram;Reviews in Cardiovascular Medicine;2024-07-16

2. Amiloride lowers plasma TNF and interleukin-6 but not interleukin-17A in patients with hypertension and type 2 diabetes;American Journal of Physiology-Renal Physiology;2024-07-01

3. Atherosclerosis and inflammation: therapeutic targets and ways of correction;The Clinician;2024-06-23

4. Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets;Signal Transduction and Targeted Therapy;2024-05-31

5. The novel vaccines targeting interleukin-1 receptor type I;International Immunopharmacology;2024-05